Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$20.07 + 0.34 (1.72%)
Exchange :NASDAQ
Volume :11,929
Today's Open$19.61
Previous Close$19.73
Data as of March 23, 2018 10:28 a.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $20.07 with a 52 week high of $23.97 and a 52 week low of $8.00.

Recent Press Releases

March 09, 2018

Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference read more

March 07, 2018

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results read more

March 06, 2018

FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia read more

Upcoming Events

There are currently no events scheduled.


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.